Skip to main content
. 2017 May 9;8(40):66975–66986. doi: 10.18632/oncotarget.17756

Figure 7. ABCA13 confers drug resistance of RCC and correlates with the overall survival of RCC patients.

Figure 7

(A) ABCA13 was knock-downed in 786O KD and 769P cells, and knock down efficiency was measured by qRT-PCR. (B) SPs were determined and compared in 786O KD cells transfected with shCon and shABCA13 plasmid. (C) 786O KD or 769P cells were transfected with shCon or shABCA13 plasmid then treated with Temsirolimus for 72 h and the relative cell survival was measured by MTT assay for determining IC50 using Graphpad Prism. (D) The levels of miR-138, ABCA13 and EZH2 expression in normal versus tumor tissues from TCGA were compared. The asterisk (*) indicates statistical significance (p < 0.05) between tumor and normal; # indicates statistical significance (p < 0.05) between higher grade and G1. (E) Overall survival of high- and low- ABCA13/EZH2 groups from TCGA was analyzed. N = 468, p value was obtained from two-sided log-rank tests.